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Complete cavity collapses were observed on CT scans in 4 of 
the 5 cases. All patients showed improvements in their clini-
cal status, and sputum smears became negative within 3–5 
months. There were no severe short- or long-term complica-
tions. The valves were removed in 3 of the 5 patients after 8 
months on average; there was no relapse after 15 months of 
follow-up.  Conclusion: These data suggest that endobron-
chial valves are likely to be useful adjuncts to the treatment 
of therapeutically difficult patients. More data are required 
to confirm our findings.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 In the 1880s, Dr. Carlo Forlanini devised an apparatus 
to create artificial pneumothorax in patients as treatment 
for pulmonary tuberculosis. The apparatus brought air 
into the pleural space using a Saugmann pneumothorax 
needle. A water manometer measured the pleural pres-
sure and air volume  [1] ( fig. 1 ). For many years, this form 
of acute lung collapse was the principal method of TB 
treatment. By decreasing oxygenated air volume, the aims 
were to impede the spread of the aerobic microorganisms 
and to reduce mechanical injury to the lung  [2] . After the 
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 Abstract 
 Background: The poor treatment outcomes of multidrug-
resistant tuberculosis (TB) and the emergence of extensively 
drug-resistant TB and extremely and totally drug-resistant 
TB highlight the urgent need for new antituberculous drugs 
and other adjuvant treatment approaches.  Objectives: We 
have treated cavitary tuberculosis by the application of en-
dobronchial one-way valves (Zephyr ® ; Pulmonx Inc., Red-
wood City, Calif., USA) to induce lobar volume reduction as 
an adjunct to drug treatment. This report describes the fea-
sibility, effectiveness and safety of the procedure.  Methods: 
Patients with severe lung destruction, one or more cavities 
or those who were ineligible for surgical resection and 
showed an unsatisfactory response to standard drug treat-
ments were enrolled. During bronchoscopy, endobronchial 
valves were implanted in the lobar or segmental bronchi in 
order to induce atelectasis and reduce the cavity size.  Re-
sults: Four TB patients and 1 patient with atypical mycobac-
teriosis were treated. The mean patient age was 52.6 years. 
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review of his experience in 1882, Carlo Forlanini  [3] 
helped to popularize the procedure. Although no rigor-
ous studies assessing or proving the efficacy of this tech-
nique were done, more than 100,000 patients with pul-
monary tuberculosis were treated by induced pneumo-
thorax over the next 25 years  [4–6] .
 The discovery of streptomycin in 1943 began a new era 
of treatment  [7] , after which new drugs have been added 
to the therapeutic arsenal, making collapse therapy non-
relevant. However, the combination of modern medical 
management together with Forlanini’s induced pneumo-
thorax has never been fully investigated apart from a 2006 
study from Russia, which showed that the use of artificial 
pneumothorax as adjunctive treatment in patients with 
multidrug-resistant tuberculosis (MDR-TB) could lead 
to improved outcomes  [8] . Several clinical situations 
could benefit from non-pharmacological complementary 
therapies, such as the management of some sequelae and 
complications of difficult-to-treat TB, MDR-TB and ex-
tensively drug-resistant tuberculosis (XDR-TB), all of 
which have a high risk of complications and death. MDR-
TB is defined as TB caused by  Mycobacterium tuberculo-
sis that is resistant to at least isoniazid and rifampicin, and 
XDR-TB  [9] as resistance to fluoroquinolone and one 
second-line injectable drug (capreomycin, kanamycin or 
amikacin). The term XDR-TB was used for the first time 
in March 2006, in a report jointly published by the US 
Centers for Disease Control and Prevention (CDC) and 
the WHO to describe a disease caused by strains of  M. 
tuberculosis that were resistant not only to isoniazid and 
rifampicin (i.e. MDR-TB) but also to at least 3 of the 6 
classes of second-line anti-TB drugs (aminoglycosides, 
polypeptides, fluoroquinolones, thioamides, cycloserine 
and para-aminosalicylic acid)  [10, 11] .
 Totally drug-resistant tuberculosis has been described 
in Iran, India and South Africa  [12–15] . Despite the ad-
vent of bedaquiline, failures to treatment are already 
emerging, such as a recent case report of a patient who 
developed resistance to both bedaquiline and delamanid 
(NEJM)  [16] . Thus, there is a growing population of pro-
grammatically incurable TB that is expanding in coun-
tries such as South Africa, Russia, India and China  [17, 
18] . The WHO 2015 global tuberculosis report estimates 
that 9 million new cases of tuberculosis occurred in 2013, 
an increase from the 8.6 million cases estimated for 2012 
 [19] . According to the WHO, an estimated 480,000 new 
cases of MDR-TB occurred in 2013, making up 3–5% of 
the estimated 9 million people who developed tuberculo-
sis that year. The MDR and XDR forms of tuberculosis 
greatly complicate patient management, particularly in 
resource-poor, national tuberculosis programs. MDR-TB 
treatment success rates, defined as clinical and microbio-
logical responses, are between 44 and 60%  [20] .
 The poor treatment outcomes of MDR and XDR tu-
berculosis highlight the urgent need for the development 
of new antituberculous drugs, treatment regimens and 
other adjunct treatment approaches to improve out-
comes. The treatment time for MDR-TB is longer and 
more difficult than for a typical case of TB. According to 
WHO guidelines, the recommended duration of treat-
ment is at least 20 months for most patients, which may 
be modified according to the patient’s response to thera-
py. Previously treated MDR and XDR patients should re-
ceive at least 24 months of treatment  [9] .  Among the ther-
apeutic options are second-line drugs, which, unfor-
tunately, are expensive and associated with many side 
effects. A complete course of therapy for a patient with 
MDR-TB could cost as much as 15,000 USD for drugs and 
as much as 483,000 USD for hospitalization. The low cure 
rate for MDR-TB is similar to that reported for TB treat-
ment prior to the availability of effective anti-TB drugs 
 [21] .
 Because present TB medical therapy generally proves 
to be inadequate for curing MDR-TB, adjunctive pulmo-
nary resection has been advocated in selected patients 
with localized disease such as a cavitary lesion or a single 
destroyed lobe. In these cases, the management of cavities 
consists of the combination of anti-TB chemotherapy 
and adjuvant lung resection  [22–30] .
 The most likely mechanism by which surgery is ben-
eficial is a decrease in the bacillary burden through the 
 Fig. 1. Dr. Carlo Forlanini (1847–1918) and his apparatus for cre-
ating an artificial pneumothorax (1882). 
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removal of a large area of abnormal lung parenchyma and 
poorly drug-penetrating granulomatous cavities. Thick-
walled cavitary lesions and areas of destroyed lung con-
tain up to 10 7 –10 9  M. tuberculosis  organisms even in pa-
tients who are sputum culture negative. These tubercular 
lesions are penetrated poorly by antituberculous drugs. 
Cavities act not only as huge reservoirs of  M. tuberculosis 
 infection but also as the probable site of the development 
of drug resistance. The surgical removal of cavities could 
enhance the sterilizing properties of postsurgical chemo-
therapy and increase the likelihood of treatment success 
in these selected patients  [24, 31, 32] . Kempker et al.  [33] 
demonstrated that the tuberculous cavity promotes the 
emergence of increasingly drug-resistant bacilli popula-
tions during treatment in  M. tuberculosis isolates from 
resected cavities among patients with MDR and XDR-TB.
 In patients who already have high drug resistance and 
limited treatment options, the development of further 
drug resistance could have unfavourable clinical conse-
quences. A recent systematic review and meta-analysis of 
24 comparison studies of MDR- and XDR-TB (involving 
more than 5,000 patients) found a significant association 
between surgical intervention and successful outcome 
when compared to non-surgical treatment alone (OR 
2.24, 95% CI: 1.68–2.97)  [34] . Subgroup analyses of stud-
ies involving XDR-TB patients revealed an even more 
pronounced treatment effect (OR 4.55, 95% CI: 1.32–
15.7). However, surgery frequently involves postsurgical 
complications. In addition, not all patients are suitable 
candidates. With careful patient selection, the operative 
mortality in lung resection is less than 5%  [35–40] . Com-
mon complications range in a frequency between 12 and 
30% and include bleeding, empyema, wound complica-
tions and bronchopleural fistula.
 There is thus a pressing need for new drugs and addi-
tional interventions to improve these outcomes, particu-
larly in XDR-TB.
 We hypothesized that a recent form of endobronchial 
lobar collapse therapy – the insertion of Zephyr ® (Pul-
monx Inc., Redwood City, Calif., USA) one-way endo-
bronchial valves (EBVs) – may be an effective comple-
mentary treatment in the management of MDR-TB, XDR-
TB and other forms of cavitary and difficult-to-treat TB 
and Mycobacteriosis. Because these EBVs are usually in-
dicated to induce atelectasis in chronic obstructive pul-
monary disease (COPD) patients with hyperinflated lungs 
and severe emphysema  [41–43] , we hypothesized that the 
use of Zephyr EBVs ( fig. 2 ) could also induce closure of 
the cavity by collapsing the involved lobe, resulting in de-
sirable effects such as a mechanical anaerobic environ-
ment unfavorable to the survival of  M. tuberculosis , a re-
duction in the movement of the pulmonary parenchyma 
to promote a favorable effect on tissue repair, and possibly 
an enhanced systemic pharmacological drug effect by pro-
moting drug penetration into a smaller affected area.
 In a case report published in the  International Journal 
of Tuberculosis and Lung Disease  [44] , we showed that 
Zephyr EBV placements in a patient’s lung brought a re-
duction in the cavity size in each of the treated lobes and 
a negative sputum smear and culture within 5 months 
after valve placement. No EBV-related complications oc-
curred, and the patient, having improved, was discharged 
from the hospital. On the basis of this positive experience, 
we extended the study to a larger number of patients, not 
only with MDR tuberculosis but also with difficult-to-
treat TB from other causes such as recurring atypical my-
cobacteriosis and drug reaction with eosinophilia and 
systemic symptoms (DRESS) syndrome.
 Fig. 2. Zephyr EBV. 
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 All decisions regarding the treatment (including sur-
gery or valves) were made by a multidisciplinary team of 
specialists and were approved by the Hospital for the off-
label use of Zephyr valves. The current report describes 
the authors’ experience with lobar collapse therapy by 
Zephyr unidirectional EBVs as an adjuvant treatment of 
MDR-TB, XDR-TB and other difficult-to-treat TB pa-
tients in order to evaluate the feasibility, effectiveness and 
safety of this new treatment approach.
 Materials and Methods 
 The patients included in the study were treated for TB symp-
toms at the Infectious Disease Units of the Careggi Hospital, Flor-
ence, and the Angelo Hospital, Venice, between 2010 and 2015. 
Five patients (mean age 52.6 ± 9.7 years, range 31–69, 60% female) 
were enrolled. All had severe lung destruction with one or more 
cavities, were ineligible for surgical resection and had slow or un-
satisfactory responses to standard drug treatments ( table 1 ).
 The exclusion criteria were either severe respiratory or cardiac 
failure that would prevent bronchoscopy and sedation, or a pa-
tient’s refusal to participate in the study. At the time of diagnosis, 
all TB patients had sputum specimens submitted for  M. tuberculo-
sis culture, identification and drug susceptibility testing to first-
line drugs (isoniazid, rifampicin, streptomycin and pyrazinamide). 
For all patients with MDR-TB, sputum smear and culture tests 
were repeated weekly throughout treatment. All MDR-TB isolates 
were tested further for resistance to second-line drugs, including 
kanamycin, capreomycin, ofloxacin, protionamide, cycloserine, p-
amino salicylic acid and thioacetazone.
 The EBVs used were one-way Zephyr valves, CE marked and 
approved for use by both hospitals. These devices have been used 
successfully in the treatment of pulmonary emphysema. The valves 
are positioned through a flexible bronchoscope equipped with a 
minimal operating-channel diameter of 2.8 mm that allows for in-
sertion of the delivery catheter for the specific placement of the 
valve. One patient required intubation with a rigid bronchoscope 
into which a flexible bronchoscope was inserted. The Zephyr valve 
is designed to prevent the inflow of inhaled air reaching the seg-
ment or target lobe, while allowing the outflow of air and secre-
tions during exhalation. The EBV is contained in a self-expandable 
nitinol frame that expands and facilitates adhesion and shaping to 
bronchial walls up to 8.5 mm in diameter. The result of emptying 
air from lung tissue using valves is analogous to that of lobar re-
moval with surgery. However, the absence of collateral ventilation 
(CV) is a requirement for obtaining significant lobar volume re-
duction with valves. In these patients, CV was assessed by analysis 
of fissure integrity from high-resolution CT scans. Depending on 
the patient, lobar atelectasis can be achieved by placing one or 
more valves in the lobar branches or segmental bronchus to be 
treated. One patient (Patient 1) was treated with a lobar approach 
in the middle lobe (ML) and consequently with a segmental ap-
proach in the apicoposterior branch of the left upper lobe (LUL). 
The procedures were performed under spontaneous breathing and 
conscious sedation using 2–5 mg midazolam, with the exception 
of 1 patient intubated with a rigid bronchoscope who required me-
chanical ventilation and deep sedation with propofol. The 2 pa-
tients with MDR/XDR-TB were treated under negative pressure 
and six air changes per hour inside an isolation room in the Infec-
tious Disease Department of the Careggi University Hospital (Pa-
tients 1 and 3). The 3 patients with difficult-to-treat TB were treat-
ed in the bronchoscopy suite of the Careggi University Hospital. 
The operators wore personal protection and N99 masks. Mechan-
ical respirators were not used.
 The Careggi University Hospital’s Ethics Committee approved 
the study. All patients signed an informed consent regarding the 
use of data and the possible risks associated with the procedure.
 Chest X-rays were taken before the procedure, 1 h after implan-
tation and 7 days later. Thorax CT scans were taken before the 
procedure, 30 days later and again 4–10 months after implanta-
tion. In cases where valve removal was indicated, a chest CT scan 
was taken 1 month later to evaluate the outcome. Direct sputum 
tests and sputum cultures were performed before and immediate-
ly after implantation, 7 days later and every 7 days thereafter until 
the direct sputum test became negative.
 Oxygen saturation was measured daily on all patients, and 
blood gas analysis was measured when needed.
 Table 1.  Procedures and outcomes of the 5 patients treated with Zephyr valves
Patient Sex Indication Age, 
years
Cavity 
location
Date of 
implant
Lobar
atelectasis
Closure
of cavity
Time to 
sputum
negative
Latest 
sputum 
test
Valve removal (date) 
1 F XDR-TB 29 1. RML May 19, 2011 no yes 5 months negative yes (October 11, 2012)
2. posterior 
segment
of LUL
January 11, 2012 no yes yes (November 7, 2012)
2 M M. xenopi 65 LUL June 8, 2012 target lobe
volume reduction
yes n.a. negative no
3 M MDR-TB 50 LUL November 21, 
2013
target lobe
volume reduction
partial 4 months negative no
4 F Difficult-to-treat TB 54 LUL April 30, 2014 yes yes 2 months negative yes (March 12, 2015)
5 F TB/DRESS 59 LUL October 22, 2014 yes yes n.a. n.a. yes (January 30, 2015)
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 Results 
 We report here our early experience with 5 patients 
(mean age: 52.6 ± 9.7 years, 60% female) with cavities: 4 
TB patients (1 MDR, 1 DRESS and 1 difficult-to-treat 
with extensive disease) and 1 with relapse of atypical my-
cobacteriosis. TB cavity collapses were attempted using 
Zephyr valves, while maintaining optimal anti-TB che-
motherapy treatment. The cavities were located in the 
LUL (3), right upper lobe [RUL (1)] and right ML [RML 
+ LUL (1)], and thus were also the targets of EBV place-
ments. In each patient, 2 or 3 valves were required to iso-
late a cavity. Four patients were sputum positive at the 
time of the procedure.
 The insertions of the Zephyr valves were achieved 
without complications. Complete cavity collapses were 
observed on CT scans in 4 of the 5 patients. The partial 
cavity collapse in the one patient probably resulted from 
an absence of atelectasis caused by the presence of inter-
lobar CV due to lack of integrity of lobar fissures, or from 
a possible partial lobar occlusion.
 All patients improved in clinical status after treatment. 
Sputum became negative after an average of 3.6 months 
(range: 2–5) and remained negative to the end of follow-
up (mean follow-up: 23 ± 12 months, range 6–40). There 
were no severe short or long-term complications related 
to this form of treatment, apart from 1 patient with a 
pneumothorax not requiring drainage.
 In our series, we removed the valves in 3 of the 5 pa-
tients after 4, 8 and 10 months, respectively, without in-
terrupting the process neither of cavity closure nor the 
improvement of the TB. Furthermore, we witnessed a re-
expansion of the lobes. The cases are described below, 
summarized in  table 1 and illustrated in  figures 3 and  4 .
 Patient 1 
 Patient 1 is a 29-year-old female admitted to our clin-
ic for the treatment of XDR-TB in January 2011. She was 
previously diagnosed with TB in her home country Ro-
mania in 2001, received first-line drug treatment but re-
lapsed in 2006 and 2009. In 2011, as determined by the 
drug susceptibility test, the patient was considered affect-
a b c
Before implantation Six months after the first
implantation, in ML
Four months after the
second implantation, in LUL
 Fig. 3. Patient 1: CT scans before ( a ) 
 and after ( b )  the first valve implan-
tation, and after the second valve 
implantation ( c ). 
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May 2012, before treatment August 2012, after treatmenta b
 Fig. 4. Patient 2: CT scans before ( a ) and 3 
months after ( b ) implantation. Red arrows 
and blue lines indicate the interlobar left 
fissure (colors refer to the online version 
only). 
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ed by XDR-TB and ineligible for surgery given the extent 
of her disease. Her sputum culture recorded a heavy 
growth of  M. tuberculosis . A CT scan (January 26, 2011) 
showed multiple cavities in the LUL, RML and right low-
er lobe (RLL). A drug susceptibility test demonstrated 
that the isolate was resistant to first- and second-line an-
tibacterial agents and was only susceptible to amikacin 
and linezolid. Our treatment plan was initiated in January 
2011 with (i.v.) imipenem/cilastatin, amikacin, linezolid 
and (p.o.) clofazimine. The patient showed no improve-
ment in asthenia, persistent cough, intermittent fever and 
episodes of hemoptysis. Repeated evaluation by sputum 
analysis (every 10–15 days) and CT (March 2011) failed 
to show improvement. Given the patient’s deteriorating 
condition, we considered EBV placement. Following a 
pretreatment CT scan, the decision was made to target the 
RML, where we could treat a cavity and an entire lobe 
without significantly affecting ventilation. The CT analy-
sis showed the integrity of the fissures. If successful, the 
aim was  to continue treating her other lobes. The implan-
tation in RML was performed on May 19, 2011. Using lo-
cal anaesthesia and conscious sedation, two 4-mm Zeph-
yr valves were inserted into the lateral and medial seg-
mental bronchi of the ML bronchus. On May 27, 2011, 
terizidone was added to the treatment regimen. No hy-
persecretion was observed during the bronchoscopy. At 
the 1-month follow-up, the CT scan showed a marked 
reduction in the size of the ML cavity. However, the spu-
tum culture remained positive. TMC207 bedaquiline (ex-
perimental drug) was started in October 2011. After 1 
month, the sputum smear and culture turned negative. 
The CT scan of November 2011 showed a complete clo-
sure of the RML cavity. It was then decided to remove the 
RML EBVs and to implant other valves to target a persis-
tent cavity in the LUL. On January 11, 2012, in a single 
procedure, the two EBVs were removed from the ML,  and 
a 5.5-mm Zephyr valve was placed in the apicoposterior 
branch of the LUL. This segmental approach was under-
taken as a balance between the goal of closing the cavity 
and the poor functional condition of the patient that pre-
vented exclusion of the entire lobe. The 1-month follow-
up CT scan showed a volume reduction of the segment 
and a reduction in the size of the cavity ( fig. 3 ). The pa-
tient became asymptomatic. At the 10-month follow-up 
(October 2012), the CT scan demonstrated a further re-
duction of the cavity in the LUL and a stabilization of the 
ML. All EBVs were subsequently removed on November 
7, 2012. At the 3-year follow-up (2015), the CT scan dem-
onstrated a partial reventilation of the LUL and a stabili-
zation of the RML.
 Patient 2 
 In 2009, a 65-year-old, HIV-negative male smoker 
with diagnosed emphysema was diagnosed with atypical 
mycobacteriosis and underwent a segmental resection of 
the RUL for suspected malignancy. The histology re-
vealed an atypical mycobacteriosis caused by  M. xenopi ; 
he was treated for 9 months with clarithromycin, ri-
fampin and ethambutol. In May 2011, he had a relapse of 
infiltration with a new cavity in the LUL. The sputum 
culture recorded a heavy growth of  M. xenopi . The patient 
refused to repeat antibacterial treatment. The CT scan re-
vealed that the LUL was affected by a large cavity with 
thickened walls communicating with the bronchial tree. 
The CT analysis showed the integrity of the fissures. On 
June 6, 2012, under local anesthesia, three Zephyr valves 
were inserted into the segmental bronchi of the LUL by 
flexible bronchoscope. No hypersecretion was observed. 
The chest CT scan taken 1 month later showed that the 
cavity in the LUL had decreased in size. Although no 
complete lobar atelectasis was achieved, there was a sig-
nificant reduction in the lobar volume ( fig. 4 ). The patient 
developed a pneumothorax not requiring drainage and 
rapidly recovered. There was a slight improvement in the 
results of the functional tests. Before implantation, the 
values were as follows: FEV 1 2.77 L (77%), FEV 1 /FVC 
62%, RV 3.78 L (143%), TLC 8.31 L, D LCO 66%. After im-
plantation, the following values were measured: FEV 1 
2.97 L (85%), FVC 4.95 L (108%), FEV 1 /FVC 60%, RV 
2.65 L (97%), TLC 7.76 L, D LCO 72%. The 1-year follow-
up demonstrated continuing closure of the treated lesion. 
As the patient suffered from emphysema and derived 
clinical benefit from the treatment, it was decided not to 
remove the valves. To date, the patient has remained as-
ymptomatic.
 Patient 3 
 In November 2013, a 50-year-old, HIV-negative male 
smoker diagnosed with MDR-TB had been treated with 
optimal chemotherapy from October 2013. However, the 
sputum culture recorded persistent heavy growth of 
MDR-TB in spite of the pharmacological treatment in the 
hospital with linezolid, levofloxacin, protionamide and 
cycloserin. The CT scan showed that the LUL was affect-
ed by a persistent, large cavity; the patient had 38  °  C fever 
and severe respiratory failure (room Pa O 2 : 44 mm Hg; 
 fig. 5 ). On the basis of the CT scan and the deterioration 
of respiratory conditions, it was decided to insert valves 
to collapse the LUL. The CT analysis of the fissures was 
not conclusive for the severe lung destruction. The op-
eration took place on November 21, 2013. Three Zephyr 
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valves were inserted into the segmental bronchi of the 
LUL. The chest CT scan 3 weeks after the procedure 
showed only a partial atelectasis and partial closure of the 
cavity. The patient continued to smoke and required re-
peat bronchoscopies to aspirate secretions. Despite 
achieving only a partial collapse, we decided not to re-
move the valves due to the significant clinical improve-
ments in arterial blood gas analysis (ABG) and the dys-
pnea we observed immediately after implantation and in 
the months following the operation (room Pa O 2 ; before 
treatment: 53 mm Hg; 2 weeks after treatment: 94 mm 
Hg). Sputum smears became negative within 4 months. 
The patient interrupted the pharmacological treatment in 
October 2015 and is clinically stable.
 Patient 4 
 In January 2014, a 53-year-old, HIV-negative female 
diagnosed with TB was treated with chemotherapy, but 
November 2013, before treatment
December 2013, after treatment
a
b
 Fig. 5. Patient 3: CT scans before ( a ) and 1 month after ( b ) valve implantation. 
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after 5 months of therapy, sputum culture remained pos-
itive with a heavy growth of MDR-TB. The CT scan 
showed a persistent large cavity in the LUL ( fig. 6 a). The 
CT analysis showed the integrity of the fissures. There 
were no improvements in asthenia, persistent cough, in-
termittent fever and episodes of hemoptysis. On the basis 
of the CT scan, we decided to insert 3 valves in the seg-
mental bronchi of the LUL ( fig. 6 b). The procedure took 
place on 30 April 2014, and the sputum smear turned neg-
ative within the following 2 months. We observed no hy-
persecretion during the bronchoscopy. Chest CT scans at 
1 and 4 months after implantation showed complete lo-
bar atelectasis and closure of the cavity ( fig. 6 b). During 
the months after treatment, there was an improvement in 
clinical symptoms, and the patient returned to active life 
(work) within 2 months. The EBVs were removed 10.5 
months later. The CT scan taken 3 weeks after removal 
showed a stable closure of the cavity and a welcome par-
tial reventilation of the LUL after such a long duration of 
atelectasis ( fig. 6 c).
 Patient 5 
 A female, 59 years old, with type 2 diabetes and af-
fected by TB since March 21, 2014, was diagnosed with 
DRESS syndrome on April 26, 2014, after 1 month of 
standard treatment, which forced an interruption of the 
pharmacological treatment. A CT scan at follow-up on 
September 25, 2014, demonstrated a large RUL pleuropa-
renchymal cavity ( fig. 7 a). The CT analysis showed the 
integrity of the fissures. She was asymptomatic. To re-
solve the cavity, 3 valves were implanted in the RUL on 
October 22, 2014. No hypersecretion was observed dur-
ing the bronchoscopy. On December 12, 2014, the patient 
was clinically stable, and a chest CT scan showed com-
plete RUL atelectasis with cavity closure ( fig. 7 b). On Feb-
ruary 1, 2015, on the basis of the CT scan, we decided to 
remove the valves. A chest CT scan on February 25, 2015, 
demonstrated partial reventilation of the RUL and stable 
closure of the cavity ( fig. 7 c).
 Discussion 
 In the present series of 5 patients, Zephyr EBVs were 
used to induce lobar collapse or lobar volume reduction 
of the affected lobes of patients with MDR, difficult-to-
treat TB or Mycobacteriosis concomitantly treated with 
conventional medical therapy. The result was a reduction 
in cavity sizes within 1 month after valve implants. In 
each of the treated lobes, the closure of the cavities re-
mained stable in the 12–56 months observed after im-
plantation and in the 8 months observed after valve re-
moval in the 3 cases in whom valves were removed. Some 
patients even demonstrated further clinical and ABG im-
provements. One patient had emphysema; another pa-
tient continued smoking and was likely to have COPD 
according to his clinical history, but no lung function test 
was available. The principal impact of the treatment was 
the anatomical decrease of the cavity size resulting from 
the mechanism of the valves, which is known to induce 
collapse or at least volume reduction of the treated lobe. 
In these patients, it resulted in an accelerated TB cavity 
closure. This is a welcome side effect given that the clo-
sure of a TB cavity usually takes a very long time (often 
years), together with ensuing risks of superinfection and 
relapses.
a b c
Before implantation (April 10, 2014) Four months after implantation
(September 8, 2014)
After removal of valves
(March 23, 2015)
 Fig. 6. Patient 4: CT scans before ( a ) and after ( b ) valve implantation, and after valve removal ( c ). 
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 No patient died or experienced severe adverse events 
related to valve implantation. One patient experienced a 
mild pneumothorax that resolved without drainage. All 
patients are currently alive and in a stable medical condi-
tion.
 The sputum smears and cultures turned negative 3–5 
months after EBV placement. These results could be at-
tributed to the combination of pharmacological therapy 
and the creation of atelectasis, or at least of parenchymal 
volume reduction and hypoventilation induced by the 
valves.
 The only other reports in the literature regarding the 
use of a similar approach in the treatment of tuberculosis 
come from Russia. These authors used Russian-made sil-
icone valves, which reportedly promoted stabilization 
and regression of the tubercular process. The valves were 
implanted in 89 patients with MDR-TB and in 118 pa-
tients with infiltrative pulmonary TB. The Russian sili-
cone valve was fitted outside of a 6-mm bronchoscope 
and pushed in place with the bronchoscope and a forceps 
in the instrument channel  [45–47] .
 The results of our study indicate that one-way EBV 
Zephyr valve implantation in TB patients, a much less in-
vasive approach than lung reduction surgery, is safe and 
free of severe complications. There are no major contra-
indications for this procedure apart from the high risks of 
severe respiratory or cardiac failure from the bronchos-
copy itself. Severe mucostasis seems to be a contraindica-
tion for valve therapy, as it seems to be associated with a 
higher risk of poststenotic pneumonia in the treatment of 
emphysema. In our series, we had unsatisfactory results 
plus the need for repeated mucus aspirations in Patient 3 
who had chronic bronchitis and continued to smoke.
 Adjunctive pulmonary resection has been advocated 
in selected patients with localized MDR-TB and cavitary 
lesions or a single destroyed lobe  [3, 22–31, 33] . However, 
not all patients are suitable candidates, and surgery fre-
quently involves postoperative complications. Induced 
lobar collapse with valves has the advantages of being re-
versible and of allowing reventilation of the lobe after the 
cavity has healed, as demonstrated in 3 of our patients.
 The successful use of valves for the treatment of hyper-
inflation in emphysema has been well investigated  [41, 
48, 49] . A necessary requirement for successful lobar col-
lapse is the integrity of the fissure because the likelihood 
of successful atelectasis depends upon the absence of CV 
a b cBefore implantation (September 25, 2014) After implantation (December 12, 2014) After valve removal (February 25, 2015)
 Fig. 7. Patient 5: CT scans before ( a ) and after ( b ) valve implantation, and after valve removal ( c ). 
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between the target and adjacent lobes. This can be as-
sessed before treatment with a catheter-based system 
(Chartis System; Pulmonx Corporation, Redwood City, 
Calif., USA) that measures airflow escaping the target 
lobe and, therefore, demonstrating the lack of CV  [50–
52] . In our series, we treated all patients with the goal of 
obtaining atelectasis. Our data suggest that, as with the 
treatment of emphysema, the inducement of atelectasis is 
required in order to achieve better results in the treatment 
of cavities. For this reason, the treatment must be lobar, 
preferably after exclusion of CV between lobes. Although 
we did not use Chartis, we assessed CV by fissure integ-
rity analysis from high-resolution CT scans, a method 
that has comparable accuracy  [53] .
 Nevertheless, for patients with severe DR-TB and se-
verely damaged lungs but intact fissures, this treatment 
should be approached with extreme caution, and valves 
should be removed in the case of treatment failure. In 1 
patient, a heavy smoker, the treatment achieved partial 
atelectasis and lesser radiological improvements, a result 
of smoke-induced hypersecretions that had an impact on 
the proper functioning of the valves, as was verified with 
bronchoscopy in this case. Nevertheless, he did show im-
provements in ABG and dyspnea.
 In patients with bilateral cavities, the treatment of 2 
bilateral lobes simultaneously increases the risk of bilat-
eral pneumothorax. In our study, there was 1 patient with 
bilateral cavities. Due to the high risk of pneumothorax 
following valve therapy, the bilateral valve treatment was 
performed in 2 subsequent sessions  [54] .
 One additional aspect to consider is control of infec-
tion. If this procedure is to be performed on patients with, 
or more extreme than, XDR-TB, in whom the mortality 
rate is substantial, the control of infection must be ad-
dressed. In our series, the procedure was performed on 2 
patients with MDR/XDR-TB under negative pressure, 
with 6 air changes per hour, in an isolation room in the 
Infectious Disease Department of the Careggi University 
Hospital (Patients 1 and 3). In the 3 patients with diffi-
cult-to-treat TB but no DR-TB, bronchoscopy was per-
formed in the bronchoscopy suite. The operators must 
wear personal protection measures and N99 masks.
 In our series, we removed the valves in 3 of the 5 pa-
tients, after 4, 8 and 10.5 months, respectively, without an 
impact on either the process of cavity closure or the im-
provement of the TB. After valve removal, we witnessed 
a re-expansion of the lobe. Valves were not removed in 2 
other patients who experienced continued clinical bene-
fits from the reduction of hyperinflation (the original in-
dication of valve treatment). Both of these patients were 
heavy smokers, and one had diagnosed COPD and em-
physema. At present, we do not know the duration of at-
electasis required for the successful treatment of TB; the 
duration in which the valves must remain in place to 
completely reverse the cavities remains to be investigated.
 The treatment by lobar collapse draws its inspiration 
from Forlanini’s method of lung collapse with artificial 
pneumothorax. The effects are due to the juxtaposition of 
the cavity walls; the caseous areas are rendered drier and 
the diseased surface is, at least, reduced in size. The ad-
vantage of lobar collapse with valves is that it targets a 
lobe, whereas lung collapse does not. This form of lobar 
collapse is also reversible, unlike that achieved with sur-
gery, thus allowing for lobar re-expansion and renewed 
gas exchange following valve explantation.
 At present, the main indication of lobar collapse with 
valves in our series is the presence of a localized cavity not 
responding to pharmaceutical treatment, but in the fu-
ture, other indications could be considered, such as the 
effects of toxemia in patients with MDR or severe and 
destructive TB. Lobar collapse, applicable to all patients 
with cavities in addition to the MDR indication (infiltra-
tive or cavitary TB), is especially recommended for far-
advanced cases, in particular for those manifesting a rap-
idly fatal course and showing signs of extensive excava-
tions, in order to restore the lung functionality following 
removal of the valves. Other applications might include 
Aspergillus infection and the prevention of fungal infec-
tion in residual cavities, and as a bridge to surgical inter-
vention in selected cases. Presently, there is no evidence 
supporting these indications.
 The number of classical cases with indications of pro-
gressing, marked or even advanced disease that are suit-
able for lobar collapse is low. The percentage of suitable 
cases is likely to increase if we keep in mind that most 
progressive TB cases at some time in their course must 
reach a stage when lobar collapse might be used with ad-
vantage and that a case unsuitable today might have been 
suitable yesterday, or may become so tomorrow. Al-
though our experience is of a region of the world with low 
rates of MDR-TB and difficult-to-treat TB, this proce-
dure could be of greater value and use in regions with 
higher incidences of MDR-TB or difficult-to-treat TB, or 
in other settings such as low compliance, intolerance of 
or contraindications to a drug regimen, respiratory fail-
ure, etc. The TB recurrence rate with drug treatment is 
low in the western world but elevated elsewhere.
 The general costs of MDR-TB are high, ranging from 
9,235 USD in low-income countries to 48,553 USD per 
patient treated in upper middle-income countries. Exam-
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ple costs per case for MDR-TB treatment are South Af-
rica (USD 6,772), Russia (USD 14,600) and Peru (USD 
2,400)  [55–57] . In South Africa, the per-patient cost of 
XDR-TB is USD 26,392, 4 times greater than that of 
MDR-TB and 103 times greater than that of drug-sensi-
tive TB (USD 257)  [57] .
 Therefore, the cost of valves and their implantation 
should be offset by improved outcomes (fewer relapses, 
lesser contamination) and reduced medication and hos-
pitalization expenses. EBV valve therapy is also cheaper 
than surgical lobar resection.
 Conclusions 
 Whilst limited conclusions can be drawn from these 5 
cases, the outcomes from valve treatment in our patients 
are nevertheless highly promising. EBVs may represent a 
less invasive and safer adjuvant therapy to optimal drug 
treatment than surgical lung resection and, therefore, 
could potentially be safely used in a wider population of 
TB patients, with the added advantage that the therapy is 
reversible. EBV treatment could be an important re-
sponse to the global MDR- and XDR-TB epidemic and 
the associated economic burden.
 Our early clinical experience shows that endobronchi-
al valve treatment is likely to be a useful adjunct to treat-
ing therapeutically destitute patients. More data are re-
quired to confirm these hypotheses.
 These early results need to be confirmed in a larger 
patient cohort with a comparative control group and a 
longer period of follow-up. The improvements in func-
tional status, microbiological load and the optimal time 
for valve removal after repeated sputum-negative tests, if 
needed, are questions that remain to be investigated.
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